Moriarty Frank, Hardy Colin, Bennett Kathleen, Smith Susan M, Fahey Tom
HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland.
HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland.
BMJ Open. 2015 Sep 18;5(9):e008656. doi: 10.1136/bmjopen-2015-008656.
To examine: (1) changes in polypharmacy in 1997, 2002, 2007 and 2012 and; (2) changes in potentially inappropriate prescribing (PIP) prevalence and the relationship between PIP and polypharmacy in individuals aged ≥65 years over this period in Ireland.
This repeated cross-sectional study using pharmacy claims data included all individuals eligible for the General Medical Services scheme in the former Eastern Health Board region of Ireland in 1997, 2002, 2007 and 2012 (range 338,025-539,752 individuals). Outcomes evaluated were prevalence of polypharmacy (being prescribed ≥5 regular medicines) and excessive polypharmacy (≥10 regular medicines) in all individuals and PIP prevalence in those aged ≥65 years determined by 30 criteria from the Screening Tool for Older Persons' Prescriptions.
The prevalence of polypharmacy increased from 1997 to 2012, particularly among older individuals (from 17.8% to 60.4% in those aged ≥65 years). The adjusted incident rate ratio for polypharmacy in 2012 compared to 1997 was 4.16 (95% CI 3.23 to 5.36), and for excessive polypharmacy it was 10.53 (8.58 to 12.91). Prevalence of PIP rose from 32.6% in 1997 to 37.3% in 2012. High-dose aspirin and digoxin prescribing decreased over time, but long-term proton pump inhibitors at maximal dose increased substantially (from 0.8% to 23.8%). The odds of having any PIP in 2012 were lower compared to 1997 after controlling for gender and level of polypharmacy, OR 0.39 (95% CI 0.39 to 0.4).
Accounting for the marked increase in polypharmacy, prescribing quality appears to have improved with a reduction in the odds of having PIP from 1997 to 2012. With growing numbers of people taking multiple regular medicines, strategies to address the related challenges of polypharmacy and PIP are needed.
研究:(1)1997年、2002年、2007年和2012年多重用药情况的变化;(2)爱尔兰≥65岁人群中潜在不适当处方(PIP)患病率的变化以及在此期间PIP与多重用药之间的关系。
这项重复横断面研究使用药房报销数据,纳入了1997年、2002年、2007年和2012年爱尔兰前东部健康委员会地区所有符合一般医疗服务计划资格的个体(范围为338,025 - 539,752人)。评估的结果包括所有个体中多重用药(开具≥5种常规药物)和过度多重用药(≥10种常规药物)的患病率,以及≥65岁人群中根据老年人处方筛查工具的30条标准确定的PIP患病率。
从1997年到2012年,多重用药的患病率有所增加,尤其是在老年人中(≥65岁人群中从17.8%增至60.4%)。与1997年相比,2012年多重用药的调整发病率比为4.16(95%可信区间3.23至5.36),过度多重用药为10.53(8.58至12.91)。PIP的患病率从1997年的32.6%升至2012年的37.3%。随着时间推移,高剂量阿司匹林和地高辛的处方量减少,但最大剂量的长期质子泵抑制剂大幅增加(从0.8%增至23.8%)。在控制性别和多重用药水平后,2012年发生任何PIP的几率低于1997年,比值比为0.39(95%可信区间0.39至0.4)。
考虑到多重用药的显著增加,从1997年到2012年,随着发生PIP几率的降低,处方质量似乎有所改善。随着服用多种常规药物的人数不断增加,需要采取策略应对多重用药和PIP的相关挑战。